Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people

Stefan Koudstaal, Mar Pujades-Rodriguez, Spiros Denaxas, Johannes M I H Gho, Anoop D Shah, Ning Yu, Riyaz S Patel, Chris P Gale, Arno W Hoes, John G Cleland, Folkert W Asselbergs, Harry Hemingway, Stefan Koudstaal, Mar Pujades-Rodriguez, Spiros Denaxas, Johannes M I H Gho, Anoop D Shah, Ning Yu, Riyaz S Patel, Chris P Gale, Arno W Hoes, John G Cleland, Folkert W Asselbergs, Harry Hemingway

Abstract

Aims: The prognosis of patients hospitalized for worsening heart failure (HF) is well described, but not that of patients managed solely in non-acute settings such as primary care or secondary outpatient care. We assessed the distribution of HF across levels of healthcare, and assessed the prognostic differences for patients with HF either recorded in primary care (including secondary outpatient care) (PC), hospital admissions alone, or known in both contexts.

Methods and results: This study was part of the CALIBER programme, which comprises linked data from primary care, hospital admissions, and death certificates for 2.1 million inhabitants of England. We identified 89 554 patients with newly recorded HF, of whom 23 547 (26%) were recorded in PC but never hospitalized, 30 629 (34%) in hospital admissions but not known in PC, 23 681 (27%) in both, and 11 697 (13%) in death certificates only. The highest prescription rates of ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists was found in patients known in both contexts. The respective 5-year survival in the first three groups was 43.9% [95% confidence interval (CI) 43.2-44.6%], 21.7% (95% CI 21.1-22.2%), and 39.8% (95% CI 39.2-40.5%), compared with 88.1% (95% CI 87.9-88.3%) in the age- and sex-matched general population.

Conclusion: In the general population, one in four patients with HF will not be hospitalized for worsening HF within a median follow-up of 1.7 years, yet they still have a poor 5-year prognosis. Patients admitted to hospital with worsening HF but not known with HF in primary care have the worst prognosis and management. Mitigating the prognostic burden of HF requires greater consistency across primary and secondary care in the identification, profiling, and treatment of patients.

Trial registration: NCT02551016.

Keywords: Acute hospital admission; Electronic health records; Epidemiology; Heart failure; Primary care; Prognosis.

© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Figures

Figure 1
Figure 1
Venn diagram showing the number and percentage of records in primary care (CPRD), hospital admissions (HES), and mortality registry (ONS) for heart failure across three national sources in England, UK (n = 89 554).
Figure 2
Figure 2
Kaplan–Meier survival curves showing the survival following heart failure (HF) recorded in primary care, acute hospital admissions, or both, for all‐cause mortality (A and D), cardiovascular mortality (B and E), and HF as cause of death (C and F). (A–C) Ninety‐day mortality; (D–F) 5‐year mortality in patients surviving the first 3 months. PC, primary care.
Figure 3
Figure 3
Cox proportional hazard models for association between electronic health record record for heart failure (HF) and 5‐year all‐cause, cardiovascular, and HF‐related mortality, stratified by HF recorded in primary care, acute HF hospital admissions, or both. CI, confidence interval; HR, hazard ratio.

References

    1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137–1146.
    1. Bolmsjö B, Mölstad S, Östgren C, Midlöv P. Prevalence and treatment of heart failure in Swedish nursing homes. BMC Geriatr 2013;13:118.
    1. Van Riet EES, Hoes AW, Limburg A, Landman MA, Van Der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014;16:772–777.
    1. Avaldi VM, Lenzi J, Castaldini I, Urbinati S, Di Pasquale G, Morini M, Protonotari A, Maggioni AP, Fantini MP. Hospital Readmissions of patients with heart failure: the impact of hospital and primary care organizational factors in Northern Italy. PLoS One 2015;10:e0127796.
    1. Rothwell PM. External validity of randomised controlled trials: ‘to whom do the results of this trial apply?’ Lancet 2005;365:82–93.
    1. Zarrinkoub R, Wettermark B, Wändell P, Mejhert M, Szulkin R, Ljunggren G, Kahan T. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail 2013;15:995–1002.
    1. Ohlmeier C, Mikolajczyk R, Frick J, Prütz F, Haverkamp W, Garbe E. Incidence, prevalence and 1‐year all‐cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons. Clin Res Cardiol 2015;104:688–696.
    1. Mosterd A, Cost B, Hoes AW, Bruijne M, Deckers JW, Hofman A, Grobbee DE. The prognosis of heart failure in the general population. The Rotterdam Study. Eur Heart J 2001;22:1318–1327.
    1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long‐term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397–1402.
    1. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015;175:996–1004.
    1. Bleumink G, Knetsch A, Sturkenboom M, Straus S, Hofman A, Deckers J, Witteman J, Stricker B. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. Eur Heart J 2004;25:1614–1619.
    1. Meta‐analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta‐analysis. Eur Heart J 2012;33:1750–1757.
    1. Muntwyler J, Abetel G, Gruner C, Follath F. One‐year mortality among unselected outpatients with heart failure. Eur Heart J 2002;23:1861–1866.
    1. Gomez‐Soto FM, Andrey JL, Garcia‐Egido AA, Escobar MA, Romero SP, Garcia‐Arjona R, Gutierrez J, Gomez F. Incidence and mortality of heart failure: a community‐based study. Int J Cardiol 2011;151:40–45.
    1. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D. Predicting mortality among patients hospitalized for heart failure derivation and validation of a clinical model. JAMA 2003;290:2581–2587.
    1. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population‐based study. Arch Intern Med 2002;162:1689–1694.
    1. Chang P, Chambless L, Shahar, Bertone , Russel, Ni , He, Mosley , Wagenknecht, Samdarshi , Wrick, Rosamond WD . Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 2014;113:504–510.
    1. Kristensen SL, Jhund PS, Køber L, Preiss D, Kjekshus J, McKelvie RS, Zile MR, Anand IS, Wikstrand J, Wedel H, Komajda M, Carson PE, Cleland JG, McMurray JJ. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail 2015;17:169–176.
    1. Komajda M, Tavazzi L, Swedberg K, Bohm M, Borer JS, Moyne A, Ford I. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of SHIFT. Eur J Heart Fail 2016;18:1182–1189.
    1. Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population‐based study. Eur Heart J 2008;29:339–347.
    1. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2004;43:317–327.
    1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–259.
    1. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community‐based cohort: 11‐year follow‐up of PREVEND. Eur J Heart Fail 2013;34:1424–1431.
    1. Varadarajan P, Pai RG. Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2258 hospitalized patients. J Card Fail 2003;9:107–112.
    1. Hripcsak G, Albers DJ. Next‐generation phenotyping of electronic health records. J Am Med Inform Assoc 2013;20:117–121.
    1. Albers DJ, Hripcsak G, Schmidt M. Population physiology: leveraging electronic health record data to understand human endocrine dynamics. PLoS One 2012;7:e48058.
    1. Denaxas SC, Morley KI. Big biomedical data and cardiovascular disease research: opportunities and challenges. Eur Heart J ‐ Qual Care Clin Outcomes 2015;1:9–16.
    1. Denaxas SC, George J, Herrett E, Shah AD, Kalra D, Hingorani AD, Kivimaki M, Timmis AD, Smeeth L, Hemingway H. Data resource profile: cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER). Int J Epidemiol 2012;41:1625–1638.
    1. Rapsomaniki E, Shah A, Perel P, Denaxas S, George J, Nicholas O, Udumyan R, Feder GS, Hingorani AD, Timmis A, Smeeth L, Hemingway H. Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients. Eur Heart J 2014;35:844–852.
    1. Dinesh Shah A, Langenberg C, Rapsomaniki E, Denaxas S, Pujades‐Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people. Lancet 2015;385(Suppl 1):S86.
    1. George J, Rapsomaniki E, Pujades‐Rodriguez M, Shah AD, Denaxas S, Herrett E, Smeeth L, Timmis A, Hemingway H. How does cardiovascular disease first present in women and men? Circulation 2015;132:1320–1328.
    1. Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, Van Staa T, Timmis A, Hemingway H. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ 2013;2350:1–12.
    1. Von Elm E, Altman DG, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: new guidelines for reporting observational studies. BMJ 2007;13:20–22.
    1. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM. The REporting of studies Conducted using Observational Routinely‐collected health Data (RECORD) Statement. PLoS Med 2015;12:1–22.
    1. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827–836.
    1. Mathur R, Bhaskaran K, Chaturvedi N, Leon DA, van Staa T, Grundy E, Smeeth L. Completeness and usability of ethnicity data in UK‐based primary care and hospital databases. J Public Health (Bangkok) 2014;36:684–692.
    1. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4–14.
    1. Morley KI, Wallace J, Denaxas SC, Hunter RJ, Patel RS, Perel P, Shah AD, Timmis AD, Schilling RJ, Hemingway H. Defining disease phenotypes using national linked electronic health records: a case study of atrial fibrillation. PLoS One 2014;9:e110900.
    1. Rapsomaniki E, Timmis A, George J, Pujades‐Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life‐years lost, and age‐specific associations in 1.25 million people. Lancet 2014;383:1899–1911.
    1. O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF). Am Heart J 2008;156:662–673.
    1. . Routes to Diagnosis NCIN Data Briefing. 2010.
    1. Al‐Damluji MS, Dzara K, Hodshon B, Punnanithinont N, Krumholz HM, Chaudhry SI, Horwitz LI. Association of discharge summary quality with readmission risk for patients hospitalized with heart failure exacerbation. Circ Cardiovasc Qual Outcomes 2015;8:109–111.
    1. Burns EM, Rigby E, Mamidanna R, Bottle A, Aylin P, Ziprin P, Faiz OD. Systematic review of discharge coding accuracy. J Public Health (Bangkok) 2012;34:138–148.
    1. Pujades‐Rodriguez M, George J, Shah AD, Rapsomaniki E, Denaxas S, West R, Smeeth L, Timmis A, Hemingway H. Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1937 360 people in England: lifetime risks and implications for risk prediction. Int J Epidemiol 2015;44:129–141.
    1. Quint JK, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha JA. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 2013;6650:1–15.
    1. Maggioni AP, Orso F, Calabria S, Rossi E, Cinconze E, Baldasseroni S, Martini N. The real‐world evidence of heart failure: findings from 41 413 patients of the ARNO database. Eur J Heart Fail 2016;18:402–410.
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez‐Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–e239.
    1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
    1. Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, Rouleau J, Shi V, Lefkowitz M, McMurray JJ. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM‐HF trial. JACC Heart Fail 2016;4:816–822.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel